Protocol:
AAAO9505

The LESS GERD Trial For Adults Living with Severe Reflux

Gastroesophageal reflux disease (GERD) is a chronic digestive disease that affects nearly 65 million people in the United States.1 It occurs when stomach acid or stomach contents flow back into your food pipe (esophagus). The backwash (reflux) irritates the lining of your esophagus and causes GERD.2 Frequent and troublesome symptoms may include one or more of the following: heartburn, regurgitation, sleep disruption, vocal impairment, and respiratory complications.

Most individuals with GERD are successfully treated with acid blocking medications such as proton pump inhibitors (PPI). However, nearly 30% of individuals on PPI medication continue to suffer from symptoms.

If you or a loved one between the ages of 22 and 75 suffers from chronic reflux, take PPI medication, and continue to suffer from reflux symptoms, consider participating in the LESS GERD TRIAL.

The LESS GERD TRIAL will examine the effects of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System, a new minimally invasive approach to severe reflux treatment, on GERD outcomes, such as: esophageal pH (acid in the esophagus); GERD symptoms (heartburn and regurgitation); and effect of GERD on overall quality of life.

Visit www.lessgerd.com for more information about the trial and to take the online Self-Screening Test to determine if you may be eligible to participate in the study.
Download Flyer »
  1. National Institute of Diabetes and Digestive and Kidney Diseases, Definition and Facts for GER and GERD,
    http://www.niddk.nih.gov/health-information/health-topics/digestive-dis…. Accessed June 9, 2016.
  2. Mayo Clinic, Diseases & Conditions: GERD, http://www.mayoclinic.org/diseases-conditions/gerd/basics/definition/co…. Accessed May 24, 2016.

Are you Eligible? (Inclusion Criteria)

The LESS GERD TRIAL is open to patients who fit the following requirements:

  • Male or female
  • 22-75 years of age
  • Diagnosed with GERD
  • No prior surgery involving the esophagus
  • Taking PPI medication (Maximal dose) 
  • GERD symptoms are not completely resolved by PPI, or intolerant to the PPI

Specialty Area(s)

Gastroenterology
Esophageal

Trial Location

Columbia University Medical Center
177 Fort Washington Ave
Suite 7-435
New York, NY 10032
United States